TRVI
NASDAQ · Pharmaceuticals
Trevi Therapeutics Inc
$11.44
+0.80 (+7.52%)
Open$10.83
Previous Close$10.64
Day High$11.74
Day Low$10.70
52W High$14.39
52W Low$4.85
Volume—
Avg Volume1.23M
Market Cap1.37B
P/E Ratio—
EPS$-0.32
SectorPharmaceuticals
Analyst Ratings
Strong Buy
18 analysts
Price Target
+91.7% upside
Current
$11.44
$11.44
Target
$21.93
$21.93
$18.04
$21.93 avg
$33.12
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 772.80M | 683.27M | 746.33M |
| Net Income | 98.54M | 104.02M | 99.75M |
| Profit Margin | 12.8% | 15.2% | 13.4% |
| EBITDA | 196.14M | 177.32M | 185.79M |
| Free Cash Flow | 50.24M | 55.58M | 60.41M |
| Rev Growth | +0.7% | +7.7% | +15.7% |
| Debt/Equity | 0.64 | 0.66 | 0.70 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |